Organisation paid for research Program year 2025 Source: CMS Open Payments

AMR Clinical

Neither a doctor nor a teaching hospital

Research payments

$99,961

204 payments

Through program year 2025, AMR Clinical is reported as receiving $99,961 in research payments, across 204 payments.

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$99,961	204

Breakdown

Who paid Research payments · program year 2025

Pfizer Inc. $99,961 204 payments

Studies the money was for Research payments · program year 2025

A Phase 3 Randomized Doubleblind Placebocontrolled Clinical Study Evaluating the Safety Tolerability Immunogenicity and Efficacy of A Variantadapted Bnt162b2 Vaccine in Healthy Participants 50 Through 64 Years of Age $80,348 172 payments
A Phase 3 Study to Evaluate the Safety Tolerability and Immunogenicity of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Adults 60 Years of Age and Older $7,987 5 payments
A Phase 3 Placebocontrolled Doubleblinded Randomized Study to Evaluate the Efficacy Safety and Tolerability of A Clostridioides Difficile Vaccine in Adults 65 Years of Age and Older $5,158 14 payments
A Phase 12 Randomized Doubleblind Trial of the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Adults 18 Years of Age and Older $2,583 2 payments
A Phase 12 Randomized Doubleblinded Study to Evaluate the Safety Tolerability and Immunogenicity of Modified Rna Vaccine Candidates Against Influenza and Covid19 in Healthy Individuals $1,818 2 payments
A Phase 3 Protocol to Investigate the Safety Tolerability and Immunogenicity of A Bnt162b2 Lp81adapted Vaccine in Children 5 Through 11 Years of Age Considered at High Risk for Severe Covid19 $1,678 5 payments
A Phase 2 Randomized Doubleblind Trial to Evaluate the Safety Tolerability and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants $259 2 payments
A Phase 1 Randomized and Phase 2 Study to Evaluate the Safety Tolerability Immunogenicity and Immunopersistence of A Clostridioides Difficile Vaccine Administered in A 2Dose Regimen With Novel Adjuvants in Healthy Adults $131 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.